ASCO 2016 Conference Review - Focus on Melanoma

In this Review:

Efficacy and safety of PD-1 blockade in metastatic uveal melanoma
Results of NEMO: a phase III trial of binimetinib versus dacarbazine in NRAS mutant cutaneous melanoma
Phase III trial of nivolumab plus ipilimumab in treatment-na├»ve patients — CheckMate-067
Pembrolizumab plus ipilimumab for advanced melanoma: the KEYNOTE-029 expansion
Pembrolizumab versus ipilimumab for advanced melanoma: KEYNOTE-006
Three-year overall survival associated with pembrolizumab in KEYNOTE-001
Genomic analysis and 3-year efficacy and safety update of COMBI-d
Anti-PD-1 therapy in patients with advanced melanoma and pre-existing autoimmune disorders
Survival outcomes of nivolumab given sequentially with ipilimumab — CheckMate-064
Avelumab in previously treated metastatic Merkel cell carcinoma: the JAVELIN study

Please login below to download this issue (PDF)

Subscribe